CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 121 enrolled
Drug / intervention
OPA-15406 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02068352
NCT02068352Phase 2Completed

A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis

Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Feb 21, 2014·Updated Nov 23, 2021

In Brief

A Phase 2 clinical trial evaluating OPA-15406 and Vehicle ointment for Atopic Dermatitis. Completed, enrolled 121 participants across 30 sites in 3 countries.

Detailed Summary

The purpose of this study is to investigate the effectiveness and safety of 2 concentrations of OPA-15406 compared to vehicle in participants with atopic dermatitis (AD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Poland, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 21, 2014
Enrollment StartJun 20, 2014
Primary CompletionJan 28, 2015
Study CompletionFeb 3, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.4 years ago

Interventions

OPA-15406drug

OPA-15406 topical ointment

Vehicle ointmentdrug

OPA-15406 1%-matching placebo topical ointment